Northwest Biotherapeutics, Inc. (NWBO)
| Market Cap | 1.44B |
| Revenue (ttm) | 1.29M |
| Net Income (ttm) | -529.82M |
| Shares Out | 725.13M |
| EPS (ttm) | -0.73 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 14 |
| Last Price | $1.71 |
| Previous Close | $1.50 |
| Change ($) | 0.21 |
| Change (%) | 14.00% |
| Day's Open | 1.51 |
| Day's Range | 1.50 - 1.74 |
| Day's Volume | 4,825,736 |
| 52-Week Range | 0.18 - 2.51 |
BETHESDA, Md., May 12, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today ann...
BETHESDA, Md., March 16, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today a...
NWBO has run an 18-year long trial in GBM, one of the deadliest of cancers. It has been mired in controversies, and it has no cash.
In a short period of time, this immunotherapy biotech could either become a multi-bagger or trade near $0.
With Data Lock just announced, Top Line Date is imminent.
About NWBO
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L that is in Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The compa... [Read more...]
| Industry Biotechnology | Founded 1996 |
| CEO Linda Powers | Employees 19 |
| Stock Exchange OTCMKTS | Ticker Symbol NWBO |
Financial Performance
In 2020, NWBO's revenue was $1.29 million, a decrease of -46.43% compared to the previous year's $2.41 million. Losses were -$529.82 million, 2,445.7% more than in 2019.